BioNano Genomics (BNGOU) vs. CareDx (CDNA) Critical Analysis

BioNano Genomics (OTCMKTS:BNGOU) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Profitability

This table compares BioNano Genomics and CareDx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNano Genomics N/A N/A N/A
CareDx -61.06% -63.64% -33.85%

Analyst Ratings

This is a summary of current ratings and target prices for BioNano Genomics and CareDx, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNano Genomics 0 0 0 0 N/A
CareDx 0 1 3 1 3.00

CareDx has a consensus price target of $35.40, indicating a potential downside of 2.64%.

Insider and Institutional Ownership

86.9% of CareDx shares are held by institutional investors. 3.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares BioNano Genomics and CareDx’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioNano Genomics N/A N/A N/A N/A N/A
CareDx $76.57 million 19.82 -$46.76 million ($1.31) -27.76

BioNano Genomics has higher earnings, but lower revenue than CareDx.

Summary

CareDx beats BioNano Genomics on 5 of the 8 factors compared between the two stocks.

BioNano Genomics Company Profile

BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. BioNano Genomics, Inc. also provides Bionano prep kits and labeling kits that provide the critical reagents and protocols needed to extract and label high molecular weight, or HMW, DNA for use with the Saphyr system; and data solutions that includes a suite of hardware and software for experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. The company was formerly known as BioNanomatrix, Inc. and changed its name to BioNano Genomics, Inc. in October 2011. The company was founded in 2003 and is headquartered in San Diego, California.

CareDx Company Profile

CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence-specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction methodology; and TruSight HLA, a high resolution solution that uses next generation sequencing methodology. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.